Xilio Therapeutics (XLO) Stock: Buy, Sell, or Hold?
XLO - Xilio Therapeutics, Inc. Common Stock
$9.01
0.10 (1.12%)
▲
5d:
-0.33%
30d:
+1.92%
90d:
-4.56%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When XLO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: XLO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: XLO shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: XLO is currently trading at $9.01, which is considered fair relative to its 30-day fair value range of $8.92 to $9.05. From a valuation perspective, the stock is trading at a discount (Forward PE: -4.0) compared to its historical average (23.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, XLO is in a uptrend. The price is currently testing key support at $8.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XLO scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $20.00 (+122.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, XLO is in a uptrend. The price is currently testing key support at $8.79. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: XLO scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $20.00 (+122.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$8.92 -
$9.05
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
88.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 122.0% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 14% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$8.92 -
$9.05
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$8.79
Resistance Level
$9.57
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.04
Wall Street Target
$20.00
(+122.0%)
Revenue Growth (YoY)
131.2%
Profit Margin
-34.1%
PE vs Historical
-4.0 vs 23.0
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 4:36 AM ET
Data refreshes hourly during market hours. Next update: 5:36 AM
Data refreshes hourly during market hours. Next update: 5:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XLO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$84 | 71 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$75 | 60 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$95 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$14 | 58 HOLD |